Scientists hunt for genetic clues to stop wasting in pancreatic cancer

NCT ID NCT05376592

Recruiting now Knowledge-focused Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study is looking for genetic differences that may explain why many people with pancreatic cancer develop severe muscle wasting (cachexia). Researchers will collect blood samples from 100 patients to analyze their DNA. The goal is to find markers that could lead to earlier detection and better treatments for this serious condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help identify genetic markers that predict cancer cachexia, leading to earlier diagnosis and better treatments for this serious complication.
What could go wrong: This is an observational study, not a treatment trial. It is small (100 participants) and early-stage, so findings may not apply to all patients or lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CACHEXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cachexia pancreatic adenocarcinoma pancreatic neoplasm Wasting Syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CACHEXIA PANCREAS ADENOCARCINOMA

Contacts and locations

Locations

Atrium Health Wake Forest Baptist Comprehensive Cancer Center
RECRUITING

Winston-Salem, North Carolina, 27103, United States
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.